The renewed challenge of antibacterial chemotherapy†

Abstract

We are currently witnessing a dramatic and alarming increase in the incidence of bacterial infections resistant to most common antibiotics. In this article, we examine briefly the background to this situation, and the mechanisms both of antibacterial action and bacterial resistance. Following this introduction is a discussion of the evolution of the various antibacterial classes and of the current approaches being adopted to keep at bay the threat of a return to a pre-antibiotic era.

References

1. A. Fleming, Br. J. Exp. Pathol., 1929, 10, 226.
2. An excellent review of β-lactamases can be found in: D. M. Livermore, Clin. Microbiol. Rev., 1995, 8, 557.
3. K. Sieradzki and A. Tomasz, FEMS Microbiol. Lett., 1996, 142, 161.
4. The data used in Fig. 1 were generated using the SCIFINDER^® programme, analysing the antibacterial patent publications for each antibiotic class by year. This approach is clearly approximative, but gives an idea of the changing emphasis of research over the last three decades.
5. For a review on the use of penicillins, see D. Nathwani and M. J. Wood, Drugs, 1993, 45, 866.
6. For a review of the evolution of the cephalosporins, and their classification by generation, see J. A. Garcia-Rodriguez, J. L. M. Bellido and J. E. G. Sanchez, Int. J. Antimicrob. Agents, 1995, 5, 231.
7. M. E. Erwin and R. N. Jones, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996, Abstr. No. F145.
8. D. H. Klaubert, J. M. Essery and J. F. Barrett, Expert Opin. Invest. Drugs, 1994, 3, 133.
9. H. Hanaki, H. Agaki, Y. Masaru, T. Otani, A. Hyodo and K. Hiramatsu, Antimicrob. Agents Chemother., 1995, 39, 1120.
10. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996, Abstr. No. F138, 139, 140, 141 and 142.
11. For a comprehensive review on the most recent developments in penem research, see A. Bryskier, Expert Opin. Invest. Drugs, 1995, 4, 705.
12. J. Birnbaum, F. M. Kahan, H. Kropp and J. S. MacDonald, Am. J. Med., 1985, 78, 3.
13. J. L. Blumer, Int. J. Antimicrob. Agents, 1997, 8, 73.
14. For an excellent review of approaches to the synthesis of key intermediates for 1β-methyl carbapenems, see A. H. Berks, Tetrahedron, 1996, 52, 331.
15. W.-B. Choi, H. R. O. Churchill, J. E. Lynch, A. S. Thompson, G. R. Humphrey, R. P. Volante, P. J. Reider and I. Shinkai, Tetrahedron Lett., 1994, 35, 2275.
16. D. H. Shih, F. Baker, L. Cama and B. G. Christensen, Heterocycles, 1984, 21, 29.
17. M. L. Greenlee, F. L. DiNinno and M. L. Hammond, WO 95-US1669.
18. For a review on carbapenem-hydrolysing β-lactamases, see B. A. Rasmussen and K. Bush, Antimicrob. Agents Chemother., 1997, 41, 223.
19. Y. Sumita and M. Fikasawa, Chemotherapy, 1996, 42, 47.
20. See, for example; B. Alcaide, C. Polanco and M. A. Sierra, Tetrahedron Lett., 1996, 37, 6901; B. Alcaide, C. Polanco, E. Saez and M. A. Sierra, J. Org. Chem., 1996, 61, 7125; B. Banik, G. V. Subbaraju, V. Gottumukkala, M. S. Manhas and A. K. Bose, Tetrahedron Lett, 1996, 37, 1363; C. Niu, T. Pettersson and M. J. Miller, J. Org. Chem., 1996, 61, 1014; S. Hanessian and G. B. Bhaskar, Bioorg. Med. Chem. Lett., 1994, 4, 2285.
21. For an overview of research into trinems (formerly known as tribactams), see, S. Biondi, in Recent Advances in the Chemistry of Anti-Infective Agents, ed. P. H. Bentley and P. J. O'Hanlon, Royal Society of Chemistry, Cambridge, 1996, p. 86.
22. For recent reviews on the biological activity of sanfetrinem, see: J. Ngo and J. Castaner, Drugs of the Future, 1996, 21, 1238; K. Singh, T. M. Coque and B. E. Murray, Antimicrob. Agents Chemother., 1996, 40, 2142; R. Wise, J. M. Andrews and N. Brenwald, ibid, 1996, 40, 1248; E. Di Modugno, I. Erbetti, L. Ferrari, G. L. Galassi, S. M. Hammond and L. Xerri, ibid, 1994, 38, 2362.
23. C. Bismara, R. Di Fabio, D. Donati, T. Rossi and R. J. Thomas, Tetrahedron Lett., 1995, 36, 4283.
24. T. Rossi, S. Biondi, S. Contini, R. J. Thomas and C. Marchioro, J. Am. Chem. Soc., 1995, 117, 9604.
25. C. Ghiron, E. Piga, T. Rossi, B. Tamburini and R. J. Thomas, Tetrahedron Lett., 1996, 37, 3891 For an analogous approach to various isomers of sanfetrinem using 3-unsubstituted 4-acetoxyazetidinone, see P. M. Jackson, S. M. Roberts, S. Davalli, D. Donati, C. Marchioro, A. Perboni, S. Provera and T. Rossi, J. Chem. Soc., Perkin Trans. 1, 1996, 2029.
26. G. Kennedy, T. Rossi and B. Tamburini, Tetrahedron Lett., 1996, 37, 7441.
27. S. Giacobbe and T. Rossi, Tetrahedron: Asymmetry, 1996, 7, 3079.
28. S. Hanessian and M. J. Rozema, J. Am. Chem. Soc., 1996, 118, 9884.
29. T. Rossi, C. Marchioro, A. Paio, R. J. Thomas and P. Zarantonello, J. Org. Chem., 1997, 62, 1653.
30. D. Andreotti, S. Biondi, R. Di Fabio, D. Donati, E. Piga and T. Rossi, Bioorg. Med. Chem. Lett., 1996, 6, 2019; R. Di Fabio, D. Andreotti, S. Biondi, G. Gaviraghi and T. Rossi, ibid, 1996, 6, 2025; R. Di Fabio, T. Rossi and R. J. Thomas, Tetrahedron Lett., 1997, 38, 3587.
31. M. E. Tranquillini, G. Araldi, D. Donati, G. Pentassuglia, A. Pezzoli and A. Ursini, Bioorg. Med. Chem. Lett., 1996, 6, 1683.
32. S. Gehanne, E. Piga, D. Andreotti, S. Biondi and D. Pizzi, Bioorg. Med. Chem. Lett., 1996, 6, 2791.
33. S. Biondi, G. Gaviraghi and T. Rossi, Bioorg. Med. Chem. Lett., 1996, 6, 525; R. Di Fabio, A. Feriani, G. Gaviraghi and T. Rossi, ibid, 1995, 5, 1235.
34. D. Andreotti, T. Rossi, G. Gaviraghi, D. Donati, C. Marchioro, E. Di Modugno and A. Perboni, Bioorg. Med. Chem. Lett., 1996, 6, 491; S. Hanessian, M. J. Rozema, G. B. Reddy and J. F. Braganza, Bioorg. Med. Chem. Lett., 1995, 6, 2535.
35. A. Padova, S. M. Roberts, D. Donati, C. Marchioro and A. Perboni, Tetrahedron, 1996, 52, 263; A. Padova, S. M. Roberts, D. Donati, C. Marchioro and A. Perboni, J. Chem. Soc., Chem. Commun., 1995, 661.
36. C. Ghiron, T. Rossi and R. J. Thomas, Tetrahedron Lett., 1997, 38, 3569.
37. For an excellent recent review on the structural modifications of glycopeptide antibiotics, see A. Malabarba, T. I. Nicas and R. C. Thompson, Med. Res. Rev., 1997, 17, 69.
38. For an excellent review of the mechanism of glycopeptide binding to its target, see D. H. Williams, Nat. Prod. Rep., 1996, 13, 469.
39. R. D. G. Cooper, N. J. Snyder, M. J. Zweifel, M. A. Staszak, S. C. Wilkie, T. I. Nicas, D. H. Mullen, T. F. Butler, M. J. Rodriguez, B. E. Huff and R. C. Thompson, J. Antibiot., 1996, 49, 575.
40. T. I. Nicas, D. H. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson and R. D. G. Cooper, Antimicrob. Agents Chemother., 1996, 40, 2194.
41. N. E. Allen, D. L. LeTourneau and J. N. Hobbs, Jr., Antimicrob. Agents Chemother., 1997, 41, 66.
42. T. D. Gootz and K. E. Brightly, Med. Res. Rev., 1996, 16, 433.
43. For a review of gyrase as a drug target, see A. Maxwell, Trends Microbiol., 1997, 5, 102.
44. X.-S. Pan and M. L. Fisher, Antimicrob. Agents Chemother., 1997, 41, 471 and references cited therein.
45. E. J. C. Goldstein, Clin. Infect. Dis., 1996, 23, S25.
46. L. S. Shen, S. K. Tanaka and D. T. W. Chu, Curr. Pharm. Design, 1997, 3, 169.
47. E. Goetschi, C. J. Jenny, P. Reindl and F. Ricklin, Helv. Chim. Acta, 1996, 79, 2219; J. Gewiz, E. Goetschi, P. Hebeisen, H. Link and T. Luebbers, EP675122, 1995.
48. F. T. F. Tsai, O. M. P. Singh, T. Skarzynski, A. J. Wonacott, S. Weston, A. Tucker, R. A. Pauptit, A. L. Breeze, J. P. Poyser, R. O'Brien, J. E. Ladbury and D. Wigley, Proteins: Struct. Funct. Genet., 1997, 28, 41 and references cited therein.
49. G. Beaucaire, J. Chemother., 1995, 7(suppl. 2), 111.
50. R. N. Jones, J. Chemother., 1995, 7(suppl. 2), 7.
51. For a review on macrolides, see A. Bryskier and C. Agouridas, Antiinfect. Drugs Chemother., 1996, 14, 147.
52. G. Bright, J. Antibiot., 1988, 41, 1029; S. Dokic, G. Kobrehel, N. Lopotar, B. Kamenar, A. Nagl and D. Mrvos, J. Chem. Res. (S), 1988, 152.
53. R. N. Jones and D. J. Biedenbach, Diagn. Microbiol. Infect. Dis., 1997, 27, 8.
54. T. Schulin, C. B. Wennerstein, R. C. Mollering, Jr and G. M. Eliopoulos, Antimicrob. Agents Chemother., 1997, 41, 1196.
55. Y. S. Or, K. Spina, M. Tufano, J. Plattner and D. Chu, Book of Abstracts, 212th ACS National Meeting, Orlando, 1996.
56. J.-C. Pechère, Drugs, 1996, 51(suppl. 1), 13.
57. G. A. Pankuch, M. R. Jacobs and P. C. Applebaum, Antimicrob. Agents Chemother., 1996, 40, 2071.
58. C. A. Wood, H. D. Mandler, B. E. Fry-Arrighy, J. Smith-Davis, A. I. Hartstein and E. A. Blumberg, Poster LB13 presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September, 1996.
59. D. Schnappinger and W. Hillen, Arch. Microbiol., 1996, 165, 359.
60. F. T. Tally, G. A. Ellestad and R. T. Testa, J. Antimicrob. Chemother., 1995, 35, 449.
61. For an excellent review on the oxazolidinones, see S. J. Brickner, Curr. Pharm. Des., 1996, 2, 175.
62. S. J. Brickner, D. K. Hutchinson, M. R. Barbachyn, P. R. Manninen, D. A. Ulanowicz, S. A. Garmon, K. C. Grega, S. K. Hendges, D. S. Toops, C. W. Ford and G. E. Zurenko, J. Med. Chem., 1996, 39, 673.
63. D. M. Gleave and S. J. Brickner, J. Org. Chem., 1996, 61, 6470.
64. A. Denis and T. Villette, Bioorg. Med. Chem. Lett., 1994, 16, 1925.
65. For a recent overview of the current status of tuberculosis research, see K. Duncan, Expert Opin. Ther. Pat., 1997, 7, 129.
66. C. Grassi and V. Peona, Eur. Respir. J., 1995, 8(suppl. 20), 714s.
67. see I. Chopra, Expert Opin. Invest. Drugs, 1996, 5, 241; E. J. Straus and S. Falkow, Science, 1997, 276, 707.
68. I. Chopra, J. Hodgson, B. Metcalf and G. Poste, J. Am. Med. Assoc., 1996, 5, 401.
69. For a review on the application of protein crystallography to drug design, see J. L. Martin, Curr. Med. Chem., 1996, 3, 419.
70. For an excellent review on bacterial virulence as a therapeutic target, see R. M. Goldschmidt, M. J. Macielag, D. J. Hlasta and J. F. Barrett, Curr. Pharm. Des., 1997, 3, 125.
71. B. B. Finlay and P. Cossart, Science, 1997, 276, 718.